Search results
Results from the WOW.Com Content Network
Lenalidomide, sold under the brand name Revlimid among others, is a medication used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes (MDS). [8] For multiple myeloma, it is a first line treatment, and is given with dexamethasone . [ 8 ]
The thalidomide molecule is a synthetic derivative of glutamic acid and consists of a glutarimide ring and a phthaloyl ring (Figure 5). [15] [16] Its IUPAC name is 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione and it has one chiral center [15] After thalidomide's selective inhibition of TNF-α had been reported, a renewed effort was put in thalidomide's clinical development.
Because they have different dose-limiting adverse effects, they can be given together at full doses in chemotherapy regimens. [1] The first successful combination chemotherapy was MOPP, introduced in 1963 for lymphomas. The term "induction regimen" refers to a chemotherapy regimen used for the initial treatment of a disease.
When it comes to drug pricing, European regulators are a tough sell. Just ask Johnson & Johnson . The U.K.'s National Institute for Health and Care Excellence, or NICE, took a pass on paying for ...
A healthy payment from big biotech Celgene Corporation helped Epizyme Inc. make one of the biggest moves in biotech so far this year. News that Epizyme Inc.'s EPZ-5676 met its proof of concept ...
In a hospital setting, an intravenous PCA (IV PCA) refers to an electronically controlled infusion pump that delivers an amount of analgesic when the patient presses a button. [4] IV PCA can be used for both acute and chronic pain patients. It is commonly used for post-operative pain management, and for end-stage cancer patients. [5]
The loss of exclusivity for its key drugs in the near future is a cause for concern
Some of the provisions required by the REMS program are training and certification of physicians allowed to prescribe the drug, requiring that the drug be administered in a hospital setting, requiring pharmacies to verify the status of patients receiving REMS drugs, requiring lab testing of patients to ensure that health status is satisfactory ...